FDA granted Breakthrough Therapy Designation for AAV2-hAQP1 for the treatment of Grade 2 and Grade 3 late xerostomia caused by radiotherapy for cancers of the upper aerodigestive tractMeiraGTx to hold ...
Research presented by Dr Anna Keegan of University College London at the ELRIG meeting in Hinxton described how improved ...
Belief BioMed ("BBM") and Grand Life Sciences Group Co., Ltd. ("Grand Life Sciences") today announced an exclusive ...
It's my pleasure to be moderating this chat with the CEO of Voyager Therapeutics, Al Sandrock, who sure many folks know well from his current role and famous roles as prior. Al, maybe we can get into ...
CEO Al Sandrock outlined several 2026 priorities in a discussion focused on the company’s tau-directed pipeline and its newer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results